Arcus Biosciences (RCUS) announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. Leerink Partners and Goldman Sachs & Co. are acting as joint book-running managers.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs
- Arcus Biosciences price target raised to $35 from $33 at Wedbush
- Arcus Biosciences price target raised to $56 from $54 at Citi
- Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
- Arcus Biosciences Reports Promising Q3 2025 Results